Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5735124 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL5738247 | 0.81 | TPMT (0.61) | TPMTRXRARXRBCA1CA2 | |
| SCHEMBL5737432 | 0.79 | CA1 (0.30) | CA1CA2 | |
| SCHEMBL5737045 | 0.78 | ALDH1A1 (0.40) | TPMTPOLBALDH1A1HPGDMEN1 | |
| SCHEMBL5735481 | 0.76 | SMN1; SMN2 (0.39) | RXRARXRBTDP1POLBALDH1A1 | |
| SCHEMBL5734568 | 0.73 | TPMT (0.46) | TPMTCA1CA2POLBHPGD | |
| SCHEMBL5737389 | 0.71 | MEN1 (0.45) | TPMTCA1CA2TDP1POLB | |
| SCHEMBL5736196 | 0.70 | TPMT (0.39) | TPMTCA1CA2TDP1POLB | |
| SCHEMBL5736466 | 0.70 | TPMT (0.42) | TPMTRXRARXRBCA1CA2 | |
| SCHEMBL5736741 | 0.70 | ESR1 (0.44) | TPMTCA1CA2TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083353-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | claimed |
| WO-2014120683-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-08-07 | — | — | WO | claimed |
| EP-1399156-B1 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS (AN) | 2006-11-22 | — | — | EP | claimed |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | LABORATOIRES SERONO SA (CH) | 2004-11-04 | — | — | US | claimed |
| US-9951024-B2 | Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170349553-A1 | SMALL- MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | UNIVERSITY OF CINCINNATI | 2017-12-07 | — | — | US | disclosed |
| US-20160083353-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| WO-2014120683-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-1399156-B1 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS (AN) | 2006-11-22 | — | — | EP | disclosed |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | LABORATOIRES SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1399156-A2 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002102359-A2 | ALKYLIDENE PYRAZOLIDINEDIONE DERIVATIVES AND USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083353-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | ARHGEF1, ARHGEF2, ARHGDIB | TPMT 3386/4885RXRA 3469/4885RXRB 3222/4885 |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | G6PC1, PPM1D, PTPRS | TPMT 996/4885RXRA 4810/4885RXRB 4758/4885 |
| US-20170349553-A1 | SMALL- MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | ARHGEF1, ARHGEF2, ARHGDIB | TPMT 3386/4885RXRA 3469/4885RXRB 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.